Overview

JAK Signaling in Depression

Status:
RECRUITING
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that Janus kinase (JAK) signaling is involved in major depression (MD) with high inflammation by determining whether its inhibition with baricitinib can improve functional connectivity in reward and motor circuits in association with improved motivation and motor function in MD patients enriched for high C-reactive protein (CRP) and anhedonia.
Phase:
PHASE2
Details
Lead Sponsor:
Emory University
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
baricitinib
Sugars